Legacy Wealth Asset Management LLC Reduces Stock Holdings in Eli Lilly and Company $LLY

Legacy Wealth Asset Management LLC lessened its holdings in Eli Lilly and Company (NYSE:LLY) by 30.4% during the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,456 shares of the company’s stock after selling 635 shares during the quarter. Legacy Wealth Asset Management LLC’s holdings in Eli Lilly and Company were worth $1,685,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Bank of America Corp DE bought a new stake in shares of Eli Lilly and Company in the 2nd quarter worth approximately $13,522,666,000. Jupiter Topco LLC bought a new position in Eli Lilly and Company during the 2nd quarter valued at approximately $4,667,180,000. Fifth Third Bancorp raised its stake in Eli Lilly and Company by 321.3% during the first quarter. Fifth Third Bancorp now owns 1,963,490 shares of the company’s stock valued at $1,805,959,000 after buying an additional 1,497,423 shares during the last quarter. Assenagon Asset Management S.A. boosted its holdings in Eli Lilly and Company by 353.7% in the first quarter. Assenagon Asset Management S.A. now owns 1,550,234 shares of the company’s stock worth $1,425,859,000 after acquiring an additional 1,208,510 shares in the last quarter. Finally, Corient Private Wealth LP bought a new stake in Eli Lilly and Company in the second quarter worth $764,116,000. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Trading Down 1.6%

Shares of NYSE:LLY opened at $1,169.77 on Friday. The company has a debt-to-equity ratio of 1.41, a current ratio of 1.35 and a quick ratio of 1.00. Eli Lilly and Company has a 1 year low of $783.85 and a 1 year high of $1,292.65. The company has a market cap of $1.10 trillion, a P/E ratio of 39.25, a PEG ratio of 1.46 and a beta of 0.46. The stock’s fifty day moving average price is $1,173.78 and its 200-day moving average price is $1,096.45.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, topping the consensus estimate of $6.40 by $1.98. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.The company had revenue of $22.97 billion during the quarter, compared to the consensus estimate of $20.82 billion. During the same period last year, the company earned $6.31 EPS. Eli Lilly and Company’s revenue for the quarter was up 47.7% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Sell-side analysts expect that Eli Lilly and Company will post 36.66 earnings per share for the current year.

Insider Activity

In other news, EVP Anat Hakim sold 5,000 shares of Eli Lilly and Company stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the completion of the sale, the executive vice president directly owned 11,875 shares in the company, valued at $14,131,250. The trade was a 29.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald Zakrowski sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the transaction, the chief accounting officer directly owned 1,526 shares of the company’s stock, valued at $1,808,325.26. The trade was a 56.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 13,500 shares of company stock valued at $15,958,170 in the last 90 days. 0.14% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

LLY has been the subject of several analyst reports. Wall Street Zen downgraded Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a report on Sunday, August 23rd. Citigroup upped their price target on shares of Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the stock a “buy” rating in a research note on Wednesday, July 15th. Sanford C. Bernstein increased their price objective on shares of Eli Lilly and Company from $1,300.00 to $1,385.00 and gave the company an “outperform” rating in a research report on Tuesday, July 14th. Guggenheim raised their price objective on shares of Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the company a “buy” rating in a research note on Friday, September 18th. Finally, UBS Group set a $1,376.00 price objective on shares of Eli Lilly and Company in a research note on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-five have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $1,313.43.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: New exploratory Phase 3b data from the TOGETHER-PsO study showed that combining Taltz (ixekizumab) with Zepbound (tirzepatide) produced broader biomarker changes than Taltz alone in adults with psoriasis and obesity. The findings could strengthen Lilly’s case for using its immunology and metabolic medicines together, though the data are early and exploratory. New Phase 3b data on Lilly’s Taltz and Zepbound
• Positive Sentiment: Cantor Fitzgerald raised its price target for LLY to $1,440 from $1,410 and maintained an “overweight” rating, signaling confidence in Lilly’s earnings growth and obesity-drug opportunity.
• Positive Sentiment: Lilly and Nvidia reportedly plan to commit up to $1 billion to an artificial-intelligence drug-discovery laboratory. The initiative could accelerate research, improve development efficiency and expand Lilly’s long-term pipeline. Nvidia and Eli Lilly commit to AI drug discovery lab
• Positive Sentiment: Analyst commentary continues to highlight potential growth beyond Mounjaro and Zepbound, including retatrutide, oncology products and other pipeline candidates. Retatrutide’s potential filing in 2027 provides a possible next catalyst for the obesity franchise.
• Neutral Sentiment: A technical report said Lilly recently moved above its 50-day moving average, suggesting improving short-term momentum. Technical signals may support sentiment but do not change the company’s fundamentals. Lilly overtook its 50-day moving average
• Negative Sentiment: Investors remain concerned about Lilly’s premium valuation, competition in the GLP-1 market, possible pricing pressure and the long regulatory timeline for next-generation drugs. Commentary also noted that future growth expectations are already substantial, increasing the risk of volatility if trial, regulatory or earnings results disappoint.

Eli Lilly and Company Profile

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer’s disease.